Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Hospital, Montpellier
With
National Cancer Institute, France
Direction Générale de l'Offre de Soins
Roche Pharma AG
In the aim to study a homogeneous cohort of patients, the investigators will only recruit patients in first line of treatment and treated by 5-FU (IV), IRINOTECAN et BEVACIZUMAB combination.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age \> 18 years
Colon or rectum adenocarcinoma (based on the histology)
Metastatic disease measurable with the RECIST 1.1 criteria
WHO performance status 0, 1 or 2
Life expectancy\>3 months when starting the treatment
Chemotherapy in metastatic 1rst line combining a protocol of conventional chemotherapy combining 5-FU and IRINOTECAN (FOLFIRI, XELIRI) associated with bevacizumab
Follow-up of at least one year
Collection of the written consent
Social security affiliation
You may not be if
2nd line chemotherapy and beyond
History of other cancers considered not cured
Active and progressive infection or other serious disease that may not allow the patient to receive the treatment
refusal to participate
Patient unable to express his consent
Pregnant women
Patient unable to be followed-up for at least one year
Current participation to another clinical trial
Patients under guardianship
Vulnerable people protected by the law
Clareo Health | COLOSPOT Study : Assessment by EPISPOT of Circulating Tumor Cells in Patients With Metastatic Colorectal Cancer
